Ozempic is the diabetes-born semaglutide; Zepbound is the tirzepatide built for weight loss at up to 22.5% average. Both slow the stomach and cut appetite, but the bigger loss on Zepbound raises the stakes on protein and nausea management. The food framework is the same; the discipline is not.
| A | B | |
|---|---|---|
| Active ingredient | Semaglutide | Tirzepatide |
| Average weight loss | ~7-15% | Up to 22.5% (SURMOUNT-1) |
| Appetite effect | Strong | Stronger |
| Protein stakes | High | Highest |
| Food rules | Protein-first framework | Same framework, stricter execution |
The same judgment framework runs across this site — protein, fiber and how heavy a food sits on a slow stomach.
| Easy on both | Risky on both |
|---|---|
|
|
For weight loss, Zepbound by a clear margin. For tolerability, Ozempic's lighter effect can be gentler. The choice is a medical one — the food framework works for both.
The target is the same on paper (1.2-1.6 g/kg/day), but the stakes are higher because total loss is bigger. Treat protein as the first priority on either drug.
The food framework carries over — protein-first, fiber, small meals. Dose adjustments and switches are a provider conversation, not a food one.
This comparison presents published trial data (STEP, SURMOUNT, SCALE, OASIS 4) and FDA label information for reference. It is not medical advice and does not recommend any medication. Prescription decisions belong to you and your healthcare provider.